CIP
CPRX

Convergence Investment Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Convergence Investment Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.87M Buy
75,682
+39,092
+107% +$931K 0.31% 115
2025
Q4 		$854K Buy
36,590
+364
+1% +$8.11K 0.17% 183
2025
Q3 		$714K Sell
36,226
-18,680
-34% -$384K 0.16% 179
2025
Q2 		$1.19M Buy
+54,906
New +$1.3M 0.3% 124
2023
Q1 		– Sell
-7,935
Closed -$148K – 195
2022
Q4 		$148K Buy
+7,935
New +$122K 0.09% 184

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Convergence Investment Partners's CPRX Position: Q1 2026 in Review

Convergence Investment Partners increased its Catalyst Pharmaceutical (CPRX) stake by 107% in Q1 2026, buying an estimated $931K and bringing the position to 75,682 shares worth $1.87M. The position accounts for 0.31% of the portfolio, ranked #115.

Convergence Investment Partners first reported a position in CPRX in Q4 2022 and has held it in 5 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Convergence Investment Partners held 75,682 shares of Catalyst Pharmaceutical worth $1.87M as of Q1 2026.
  • Convergence Investment Partners bought 39,092 Catalyst Pharmaceutical shares in Q1 2026, an estimated $931K.
  • Catalyst Pharmaceutical made up 0.31% of Convergence Investment Partners's portfolio in Q1 2026, its #115 holding.
  • Convergence Investment Partners first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 5 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Convergence Investment Partners's 13F filing for Q1 2026, filed 7 May 2026.